These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35582035)

  • 21. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.
    Roy M; Kung HJ; Ghosh PM
    Am J Cancer Res; 2011; 1(4):542-61. PubMed ID: 21984972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
    Qi XF; Zheng L; Lee KJ; Kim DH; Kim CS; Cai DQ; Wu Z; Qin JW; Yu YH; Kim SK
    Cell Death Dis; 2013 Feb; 4(2):e518. PubMed ID: 23449454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
    Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
    Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.
    Johnston SR
    Int J Gynecol Cancer; 2006; 16 Suppl 2():543-8. PubMed ID: 17010069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins inhibit blastocyst formation by preventing geranylgeranylation.
    Alarcon VB; Marikawa Y
    Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRα Pathway.
    Brindisi M; Fiorillo M; Frattaruolo L; Sotgia F; Lisanti MP; Cappello AR
    Cells; 2020 Jul; 9(8):. PubMed ID: 32751976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine resistance in breast cancer--An overview and update.
    Clarke R; Tyson JJ; Dixon JM
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):220-34. PubMed ID: 26455641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
    Zhao M; Ramaswamy B
    World J Clin Oncol; 2014 Aug; 5(3):248-62. PubMed ID: 25114842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
    Provenzano A; Kurian S; Abraham J
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms.
    Ahmadi Y; Ghorbanihaghjo A; Argani H
    Chem Biol Interact; 2017 Aug; 273():273-285. PubMed ID: 28668359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy.
    Xue L; Qi H; Zhang H; Ding L; Huang Q; Zhao D; Wu BJ; Li X
    Front Oncol; 2020; 10():1510. PubMed ID: 32974183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
    Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
    Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer.
    Bhardwaj A; Embury MD; Ju Z; Wang J; Bedrosian I
    BMC Cancer; 2022 Mar; 22(1):282. PubMed ID: 35296281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.